Analysis of Clinical Outcomes in the Node-301 Trial:

Etripamil Nasal Spray Relieves Symptoms and Reduces Emergency Room Interventions in Patients with Paroxysmal Supraventricular Tachycardia (PSVT)

Bruce S. Stambler; Francis Plat; Philip Sager; Benoit Coutu; Amritanshu Pandey; James E. Ip; Blandine Mondesert; Silvia Shardonofsky; Douglas Wight; A. John Camm on behalf of the NODE-301 Investigators.

> Piedmont Heart Institute, Atlanta, GA, USA; Milestone Pharmaceuticals, Montreal, Canada

Disclosures

- **B Stambler**: Honoraria, Consulting Fees, Contracted Grants for PIs - Milestone.
- The **NODE-301** trial and these analyses were funded by Milestone Pharmaceuticals.
- The trial was conducted and coordinated by Medpace.

Etripamil

- Novel, L-type calcium channel blocker
- Administered as a rapidly-acting nasal spray
- Being developed as a self-administered therapy to terminate AV nodal-dependent PSVT.

Phase 3 Efficacy and Safety Study of Etripamil Nasal Spray

- Rapid termination of symptomatic, sustained PSVT;
- Multi-center (US and Canada);
- Nasal spray self-administered during PSVT outside the emergency room or hospital without direct medical supervision.




ClinicalTrials.gov ID: 0346401

Study Design



Objective: Superiority of etripamil over placebo in terminating PSVT events in the outpatient setting




Documented diagnosis of PSVT with a history of episodes lasting ≥ 20 minutes


PSVT = Paroxysmal Supraventricular Tachycardia; SR = Sinus Rhythm;

NODE-301 Primary Endpoint – Time to Conversion

Kaplan-Meier analysis of time to conversion of positively-adjudicated PSVT episodes over 5 hours



NODE-301 Efficacy – Time to Conversion over 45 Minutes



Objectives

- To compare efficacy of etripamil with placebo regarding the following prospectively-defined, key secondary clinical endpoints:
 - relief of specific PSVT-related symptoms;
 - patient-reported satisfaction with treatment;
 - need for emergency room (ER) medical interventions;
 - need for additional rescue medical therapy.




Demographics



	Efficacy Population	
	Etripamil (N=107)	Placebo (N=49)
Age, years	56.9	54.3
Gender		
Female, n (%)	73 (68.2)	33 (67.3)
Male, n (%)	34 (31.8)	16 (32.7)
PSVT Duration, yrs	1.5	1.3
# PSVT in past yr	7.4	11.3
Lifetime ER visits	2.7	3.4


ER = emergency room

Specific PSVT Symptoms




SOB = shortness of breath

Relief of PSVT Symptoms




Patient-Reported Satisfaction with Study Medication (TSQM-9[®])




TSQM-9: 9-Item Treatment Satisfaction Questionnaire for Medication (Scores: 0-100).

Rescue Medical Interventions Sought for PSVT



ER Interventions (n=25): IV adenosine n=20; IV adenosine + oral verapamil n=1; IV procainamide n=1; IV diltiazem n=2; vagal-maneuver n=1. *Patient Self-Administered Rescue Medications (n=3)*: oral beta-blocker n=2; verapamil n=1.

Rescue Medical Medications by Time



Elapsed Time from drug taken to conversion with rescue intervention

* Recommended not earlier than 20 minutes after study drug administration

Summary



- Etripamil significantly improved PSVT-related symptoms.
- Satisfaction and effectiveness of at-home, nasal spray therapy for PSVT were higher for etripamil than placebo.
- Etripamil tended to reduce need for emergency room medical interventions for PSVT.
- These data support continued development of etripamil nasal spray for acute treatment of PSVT.

Thank You

BACK-UP/ ADDITIONAL SLIDES

NODE-102 Etripamil Nasal Spray Pharmacological Study

